Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Inclusion Criteria:

• Participants to provide a signed informed consent at the time of enrollment perprotocol,

• Male or female aged 18 or over at initiation of belimumab,

• Participants received belimumab in any formulation (subcutaneous or intravenous) forthe treatment of active LN prescribed as per local label in combination withstandard immunosuppressive therapy/ies at initiation of belimumab,

• Participants initiated belimumab 6 to 24 months prior to study enrollment,

• Accessibility of medical records starting at belimumab initiation (includingaccessibility of medical records for the prior 12 months and confirmatory biopsy atany time prior to belimumab initiation),

• Biopsy-confirmed LN diagnosis at any time prior to belimumab initiation fortreatment of LN

• Class III (focal LN) with or without Class V (membranous LN),

• Class IV (diffuse LN) with or without Class V,

• Class V.

Exclusion Criteria:

• Participants receiving renal replacement therapy (i.e., dialysis, kidney transplant,or those in end-stage kidney disease) at initiation of belimumab,

• Participant is concomitantly receiving another SLE targeted monoclonal antibody (MAb), or a MAb expected to compromise immune responses, at initiation of belimumab,

• Participants in a clinical trial during the observation period (with the exceptionof allowing participation in other non-interventional studies),

• Participant is pregnant at the initiation of belimumab,

• Participant with a kidney transplant at the initiation of belimumab,

• Participants will be excluded from the study if they are planning to become pregnantor are pregnant at study enrollment.